Being at the forefront of the AI evolution means setbacks as well as breakthroughs
IBM Watson Health has seen that being thought of as a pioneering company in applying artificial intelligence (AI) in healthcare can have its pros and cons, from a publicity point of view.
The company has taken a leading role in the evolution of the technology, making amendments to its approach as it goes – and in the case of its invention of the term augmented intelligence – it has led perceptions of how the technology is viewed.
"Where we're moving into now, is what we call broad AI, and that is being able to do multiple tasks in a domain"Being one of the first adopters of AI to bring back results from real-life settings has, of course, brought positive headlines.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze